Am Regent patent expiration

1. Dexferrum patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5624668 AM REGENT Iron dextran formulations
Sep, 2015

(8 years ago)




Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Market Authorisation Date: 23 February, 1996

Treatment: NA

Dosage: INJECTABLE

More Information on Dosage

DEXFERRUM family patents

Family Patents

2. Injectafer patent expiration

INJECTAFER's oppositions filed in EPO
INJECTAFER IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10519252 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(10 months ago)

US11590097 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(10 months ago)

US11291645 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(10 months ago)

US9376505 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(10 months ago)

US11123321 AM REGENT Aqueous iron carbohydrate complexes, their production and medicaments containing them
Oct, 2023

(10 months ago)

US7612109 AM REGENT Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes
Feb, 2025

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11364260 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(2 years from now)

US11478502 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(2 years from now)

US11433091 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(2 years from now)

US8895612 AM REGENT Methods and compositions for administration of iron
Jan, 2027

(2 years from now)

US7754702 AM REGENT Methods and compositions for administration of iron
Feb, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 25, 2016
New Strength(NS) Apr 28, 2024
New Patient Population(NPP) Nov 19, 2024
New Indication(I-915) May 31, 2026

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Market Authorisation Date: 28 April, 2021

Treatment: Method to treat iron deficiency in adults weighing at least 40 kg with heart failure & ny heart association class ii/iii to improve exercise capacity by administering iv ferric carboxymaltose to provi...

Dosage: SOLUTION

How can I launch a generic of INJECTAFER before it's drug patent expiration?
More Information on Dosage

INJECTAFER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Multrys patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11975022 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)

US11998565 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)

US11786548 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2024

Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient

NCE-1 date: 01 May, 2023

Market Authorisation Date: 30 June, 2021

Treatment: Neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or ...

Dosage: SOLUTION

More Information on Dosage

MULTRYS family patents

Family Patents

4. Selenious Acid patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11998565 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2024

Drugs and Companies using SELENIOUS ACID ingredient

NCE-1 date: 01 May, 2023

Market Authorisation Date: 30 August, 2021

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

SELENIOUS ACID family patents

Family Patents

5. Tralement patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11975022 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)

US11998565 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)

US11786548 AM REGENT Trace element compositions, methods of making and use
Jul, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 30, 2024

Drugs and Companies using CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE ingredient

NCE-1 date: 01 May, 2023

Market Authorisation Date: 30 June, 2021

Treatment: Adult and pediatric patients weighing at least 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or cont...

Dosage: SOLUTION

More Information on Dosage

TRALEMENT family patents

Family Patents